Last updated: February 14, 2026
Overview of the Drug
NDC 71699-0202 refers to a medication identified by the National Drug Code (NDC) system. Based on available data, this specific NDC corresponds to Amphotericin B Lipid Complex (ABLC), a broad-spectrum antifungal agent used in treating invasive fungal infections, especially in immunocompromised patients.
Key Details:
- Indications: Treatment of systemic fungal infections, including cryptococcosis, aspergillosis, and candidiasis.
- Formulation: Lipid complex formulation designed to reduce toxicity compared to conventional Amphotericin B.
- Manufacturer: Commercial production by multiple suppliers; primary branded versions include Abelcet (Galchyss) and generic equivalents.
Market Size and Dynamics
Current Market Penetration
- The antifungal market's valuation is estimated at approximately $1.2 billion in 2022, with Amphotericin B products contributing around $300 million.
- ABLC accounts for roughly 15% of Amphotericin B sales, part of the broader lipid formulation segment.
- The segment experienced a compound annual growth rate (CAGR) of about 4-6% over the past five years, driven by increased fungal infections, rising immunocompromised populations, and broader antifungal use.
Competition and Market Share
- Key competitors: Amphotericin B deoxycholate, liposomal Amphotericin B (AmBisome), and other lipid formulations.
- ABLC's market share is challenged by liposomal formulations offering better safety profiles but at higher costs.
- Pricing disparity: Liposomal products are priced 2-3 times higher than ABLC.
Regulatory and Clinical Trends
- Preference for liposomal formulations persists due to lower nephrotoxicity, limiting growth of ABLC.
- Emerging data suggest potential niche applications where ABLC remains relevant due to cost advantages.
Pricing Trends and Projections
Historical Pricing
- Average wholesale price (AWP) per vial: Ranged from $350 to $550 over the past three years.
- Reimbursement: Largely driven by hospital formularies and insurance negotiations, with costs often exceeding $1,000 per treatment course when including administration fees.
Current Price Points
- Average compounded price: Approximately $450 per vial.
- Pricing by manufacturer: Branded products typically retail at $550-$650 per vial, whereas generics may be priced around $400-$500 per vial.
Projected Price Trajectory (2023-2028)
| Year |
Estimated Range (per vial) |
Notes |
| 2023 |
$430 - $560 |
Stable, with slight increases due to inflation |
| 2024 |
$440 - $570 |
Possible modest increase in manufacturing costs |
| 2025 |
$445 - $580 |
Competitive pressures from generics |
| 2026 |
$445 - $590 |
Slight upward pressure due to inflation |
| 2027 |
$450 - $600 |
Increased demand amid fungal infection outbreaks |
| 2028 |
$455 - $610 |
Stabilization as market matures |
Key Market Drivers
- Increase in fungal infections: Rising incidence of invasive fungal diseases among immunocompromised patients.
- Cost considerations: Healthcare systems seek cheaper alternatives over liposomal formulations, supporting sustained demand for ABLC.
- Regulatory landscape: No recent major label changes; patent expirations for certain brands may increase generic availability.
- Clinical preference shifts: Continued favor for formulations with better safety profiles, but cost sensitivity remains a key factor for ABLC.
Risks to Price Stability
- Generic proliferation: Will increase competition, potentially lowering prices.
- Regulatory changes: New safety or efficacy data could alter prescribing patterns.
- Market consolidation: Potential mergers or acquisitions could impact supply, pricing, and distribution.
Summary
NDC 71699-0202, identified as Amphotericin B Lipid Complex, exhibits a stable but competitive market. Pricing remains influenced by safety, efficacy, and cost factors. Expectations favor gradual price increases, tempered by generics and competitive pressures. The drug sustains niche demand, particularly in cost-sensitive settings, despite the dominance of liposomal formulations.
Key Takeaways
- The global antifungal market valued at over $1.2 billion includes ABLC as a significant, albeit niche, component.
- ABLC's market share persists at roughly 15% within the Amphotericin B segment.
- Pricing is projected to increase gradually, with values ranging from $430 to $610 per vial by 2028.
- Competition from liposomal formulations and generics exerts downward pressure on prices.
- Demand grows with fungal infection rates, yet clinical preferences favor safer, more expensive formulations.
FAQs
Q1: What are the main competitors to Amphotericin B Lipid Complex?
A1: Liposomal Amphotericin B (AmBisome), Amphotericin B deoxycholate, and other generic liposomal or lipid formulations.
Q2: How does the safety profile of ABLC compare to liposomal formulations?
A2: ABLC has a higher nephrotoxicity risk than liposomal products, impacting clinical prescribing.
Q3: What factors influence the pricing of this drug?
A3: Manufacturing costs, competition from generics, hospital and insurance negotiations, and clinical demand.
Q4: Are there new regulatory developments impacting ABLC?
A4: No recent major regulatory changes; ongoing clinical data may influence future acceptance.
Q5: How might market dynamics change in the next five years?
A5: Increased generic availability may lower prices, while rising infection rates could sustain demand.
Sources:
[1] Market research reports on antifungal drugs.
[2] CDC updates on invasive fungal infections.
[3] IMS Health Integrated Data.
[4] FDA drug approvals and label updates.
